CRISPR

YTD

ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA.

CEO

Samarth Kulkarni

CEOSamarth Kulkarni

Employees

393

Employees393

Headquarters

Zug, Zug

HeadquartersZug, Zug

Founded

2013

Founded2013

Employees

393

Employees393

CRSP Key Statistics

Market cap

6.19B

Market cap6.19B

Price-Earnings ratio

-12.39

Price-Earnings ratio-12.39

Dividend yield

—

Dividend yield—

Average volume

2.69M

Average volume2.69M

High today

$68.88

High today$68.88

Low today

$66.85

Low today$66.85

Open price

$68.55

Open price$68.55

Volume

997.33K

Volume997.33K

52 Week high

$78.48

52 Week high$78.48

52 Week low

$30.04

52 Week low$30.04

CRSP News

Nasdaq 1d

December 5th Options Now Available For CRISPR Therapeutics

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options begin trading today, for the December 5th expiration. At Stock Options Channel , our YieldBoo...

Simply Wall St 4d

Is CRISPR Therapeutics' US$600 Million Stock Sale and CTX460 Results Shaping Its Path as a Gene Editing Leader?

In October 2025, CRISPR Therapeutics announced new preclinical results for its SyNTase™ gene editing platform targeting Alpha-1 Antitrypsin Deficiency, alongsid...

Analyst ratings

57%

of 30 ratings

Buy

56.7%

Hold

40%

Sell

3.3%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Intellia Therapeutics